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ABSTRACT: 13C magnetic resonance spectroscopy and
spectroscopic imaging measurements of hyperpolarized 13C
label exchange between exogenously administered [1-13C]-
pyruvate and endogenous lactate, catalyzed by lactate
dehydrogenase (LDH), has proved to be a powerful approach
for probing tissue metabolism in vivo. This experiment has
clinical potential, particularly in oncology, where it could be
used to assess tumor grade and response to treatment. A
limitation of the method is that pyruvate must be administered in vivo at supra-physiological concentrations. This problem can
be avoided by using hyperpolarized [1-13C]lactate, which can be used at physiological concentrations. However, sensitivity is
limited in this case by the relatively small pyruvate pool size, which would result in only low levels of labeled pyruvate being
observed even if there was complete label equilibration between the lactate and pyruvate pools. We demonstrate here a more
sensitive method in which a doubly labeled lactate species can be used to measure LDH-catalyzed exchange in vivo. In this
experiment exchange of the C2 deuterium label between injected hyperpolarized L-[1-13C,U-2H]lactate and endogenous
unlabeled lactate is observed indirectly by monitoring phase modulation of the spin-coupled hyperpolarized 13C signal in a
heteronuclear 1H/13C spin−echo experiment.
■ INTRODUCTION
Dynamic nuclear polarization (DNP) of 13C-labeled cell sub-
strates, which enhances their sensitivity to detection in vivo by
over 10,000-fold, has shown considerable promise for metabolic
imaging in vivo, particularly in the field of cancer.
1,2 The most
widely used substrate to date has been hyperpolarized
[1-13C]pyruvate, which has been used for early noninvasive
detection of tumor response to drug treatment
3,4 and
assessment of tumor grade.
5 Intravenous injection of hyper-
polarized [1-13C]pyruvate results in exchange of the hyper-
polarized 13C label with endogenous lactate in the reaction
catalyzed by lactate dehydrogenase (E.C. 1.1.1.27) (LDH).
Although there will be some net conversion of the injected
pyruvate into lactate, the equilibrium constant for the reaction
is such that chemical near-equilibrium is achieved with only a
small net conversion of pyruvate into lactate (see Supporting
Information in ref 3), which is then followed by exchange of the
hyperpolarized 13C label between the steady-state near-
equilibrium pyruvate and lactate pools. The evidence that this
is an exchange reaction, which is discussed in ref 2 is
summarized in the following. LDH has long been known to
catalyze a reaction that is near-to-equilibrium in the cell.
6
Addition of exogenous lactate has been shown to increase the
isotope exchange velocity between pyruvate and lactate,
increasing the detectable 13C label in the lactate pool.
3 This
is incompatible with net flux, where addition of lactate would
result in product inhibition and a decrease in the rate of lactate
labeling, but is consistent with isotope exchange, where the
resulting increase in the near-equilibrium NADH concentration
stimulates the exchange velocity of the enzyme.
7 The exchange
has been demonstrated directly in tumor cell suspensions by
using [3-13C]pyruvate and unlabeled lactate and detecting the
presence of the 13C label in the methyl group via splitting of the
methyl proton resonance due to 13C−1H spin−spin coupling.
The total pyruvate pool size remained relatively constant, while
there was a decrease in the concentration of the 13C-labeled
species and an increase in the 12C-labeled species. There were
nearly reciprocal changes in the concentrations of the 12C- and
13C-labeled lactate species (see Supporting Information in 3).
Exchange has also been demonstrated in vivo using magnet-
ization transfer experiments in tumors displaying signals from
hyperpolarized [1-13C]pyruvate and lactate following injection
of a tumor-bearing animal with hyperpolarized [1-13C]pyruvate.
Inversion of the lactate signal resulted in an increased rate of
decay of the pyruvate resonance, demonstrating flux of
hyperpolarized 13C label from lactate into the pyruvate pool.
8
Recognizing that this is an exchange reaction explains
observations made in vivo with hyperpolarized [1-13C]pyruvate.
Thus, tumors show relatively high levels of lactate labeling since
they tend to have large endogenous lactate pools, which
provides a large pool for the label to exchange into and also
increases the rate of the LDH-catalyzed reaction by increasing
the NADH concentration.
7 Tumors also express high levels of
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hypoxia.
9 These correlations with LDH-A activity and lactate
pool size can explain why lactate labeling is correlated with
tumor grade.
5 Decreases in LDH activity and lactate and
NAD(H) concentrations post-therapy also explain why
measurements of the kinetics of lactate labeling following
injection of hyperpolarized [1-13C]pyruvate can be used to
assess early treatment response in tumors.
3,4,7
A potential limitation of the hyperpolarized [1-13C]pyruvate
experiment is that pyruvate is injected at supra-physiological
concentrations. In preclinical studies pyruvate has been injected
at a whole blood concentration of ∼8 mM,
3 assuming a mouse
blood volume of 95 mL/kg,
10 whereas the physiological plasma
pyruvate concentration is ∼0.2 mM.
11 In the first clinical trial of
hyperpolarized [1-13C]pyruvate, where the aim was to use it to
detect treatment response in prostate cancer, pyruvate has been
injected at 0.43 mL/kg of a 250 mM solution (Clinical-
Trials.gov Identifier: NCT01229618), which equates to a whole
blood concentration of ∼1.5 mM, assuming a blood volume of
70 mL/kg,
12 whereas the concentration of pyruvate in whole
human blood from fasted individuals has been measured at
0.061 ± 0.024 mM.
13 Although there has been no evidence of
toxicity at these pyruvate concentrations, which is probably
because the pyruvate clears quickly from the circulation, it
would nevertheless be desirable to administer the labeled
substrate at concentrations that are within the physiological
range. Lactate is present in mouse plasma at ∼4m M
11 and in
human blood at 0.92 ± 0.26 mM, although this can rise to
much higher levels following exercise (1−5 mM);
14 therefore,
monitoring lactate−pyruvate exchange using hyperpolarized
[1-13C]lactate should be a desirable option. The sensitivity of
this experiment is limited, however, by the relatively small size
of the pyruvate pool.
15 Thus, even if the exchange were very
fast and there were complete label equilibration between the
lactate and pyruvate pools within the lifetime of the
hyperpolarized signal, the amount of detectable signal would
be limited by the size of the pyruvate pool. Our solution to this
problem is to use a doubly labeled lactate molecule,
[1-13C,U-2H]lactate, in which the LDH-catalyzed exchange of
the deuterium label at the C2 position with endogenous
unlabeled lactate (Figure 1) is monitored through phase
modulation of the spin- coupled hyperpolarized 13C resonance
in a heteronuclear 13C/1H spin−echo experiment (Figure 2).
Initially, exchange of deuterium will be between the two labeled
lactate species,
16 although in the longer term the deuterium will
exchange with solvent water.
17
■ METHODS
Synthesis of L-[1-13C1,2-1H,3-2H3]-, and L-[1-13C1,U-2H]Lactate.
The deuterated lactate species were prepared as described previ-
ously for L-[2-1H,3-2H3] and L-[U-2H]lactate.
17,18 Briefly, 1 g sodium
L-[1-13C1]lactate (CIL, Massachusetts, USA or Sigma Aldrich,
Gillingham, UK) as a 20% w/v solution in water was lyophilized
and reconstituted in 85 mL D2O containing 0.1 M sodium phosphate
buffer (pH* = 6.0), 3 mM DTT, 0.5 mM disodium EDTA and
1.5 mM NAD+ (lithium salt), lactate dehdyrogenase (1 kU, rabbit
muscle, Sigma Aldrich, Gillingham, UK) and lipoamide dehydrogenase
(75 U, pig heart, Calzyme, San Luis Obispo, CA, USA). The mixture
was incubated at 37 °C in the dark for 2 weeks, by which time >97% of
the C2 protons had exchanged for deuterons (by comparison of the
13C and 1H NMR integrals in fully relaxed spectra). The mixture was
heated to 100 °C for 10 min and the precipitated protein removed by
filtration through a 0.22 μm pore size membrane. To the filtrate, 0.15 g
(1.7 mmol) [1-13C]pyruvic acid (CIL, Massachusetts, USA) was added
with enough disodium phosphate to increase the phosphate
concentration to 200 mM. The pH* was raised to 7.7 with 9% w/v
LiOD in D2O; 600 mg (0.9 mmol) NAD+ (lithium salt) and 1 kU of
lactate dehydrogenase and glutamate−pyruvate transaminase (Roche,
Burgess Hill, UK) were added. The mixture was incubated at 37 °Ci n
the dark for 2 weeks, after which time >96% of the C3 protons had
exchanged for deuterons. For the preparation of L-[1-13C1,3-2H3]-
lactate, sodium L-[1-13C1]lactate was incubated in this latter mixture.
The zinc salt of lactate was obtained by acidification of the solution
with 32% HCl, followed by neutralization with basic zinc carbonate.
The resulting zinc lactate was purified by recrystallization from water/
ethanol. The sodium salt was prepared using an ion-exchange resin
(Dowex 50Wx8, Na+ form) and then lyophilized. The lactate
concentration was determined by enzymatic assay
19 and by 1H and
13C NMR spectroscopy. The lactate purity was ≥90%, and the yield
was 73% for perdeuterated lactate and 75% for the [1-13C,3-2H]lactate.
NMR Spectroscopy in Vitro. Experiments were performed at
9.4 T using a vertical bore magnet (Oxford Instruments) interfaced to
Varian UnityInova console (Palo Alto) and a 10 mm 13C/1H probe. A
13C/1H heteronuclear spin−echo experiment was used with a 4 ms
adiabatic 13C BIR4 180° refocusing pulse
20 followed immediately by a
10 ms hyperbolic secant (R = 10) 1H inversion pulse with the power
adjusted either to zero or optimized to provide adiabatic inversion
(Figure 2). The excitation profile of the 1H pulse was centered at 4.11
ppm, in order to selectively invert the C2 resonance without disturbing
the C3 resonance at 1.33 ppm. The experiment was also performed
with the 1H excitation profile centered at 1.33 ppm. A series of spectra,
with echo times varying between 50 and 600 ms, were acquired into
2048 complex points with an 8 kHz spectral width and a repetition
time of 180 s. The 13C T1’s and T2’s were measured at thermal
equilibrium using inversion recovery and Carr−Purcell−Meiboom−
Gill pulse sequences respectively.
Hyperpolarization of L-[1-13C1]-, L-[1-13C1,2-1H,3-2H3]-, and
L-[1-13C1,U-2H]Lactate and [1-13C]Pyruvate. To aqueous solutions
of L-[1-13C1]-, [1-13C1,2-1H,3-2H3]-, or [1-13C1,U-2H]sodium lactate
(∼50% w/v) were added trityl radical (OX063; GE Healthcare,
Amersham, UK) and gadolinium chelate (Dotarem; Guerbet, Roissy,
France) to final concentrations of 15 mM and 1.2 mM, respectively.
DMSO, to a final concentration of 30% w/v, was present in order to
ensure glass formation in the solid state. [1-13C]Pyruvic acid samples
(44 mg) contained 15 mM trityl radical and 1.4 mM of a gadolinium
chelate (Dotarem). Samples were hyperpolarized as described
previously.
3 Briefly, the sample was frozen rapidly under liquid helium
at 3.35 T in an alpha-prototype hyperpolarizer (GE Healthcare Plc,
Amersham, UK) at a pressure of ∼1 mbar (∼1.2 K). Polarization was
transferred to the 13C nuclei with irradiation at 93.965 GHz (100 mW)
Figure 1. Oxidation of lactate and reduction of pyruvate in the
reaction catalyzed by lactate dehydrogenase. The hydrogen that is
exchanged for deuterium in lactate ((2)H) and the coupling constants
for spin−spin coupling between the methylene and methyl protons
and the 13C at the C1 position of lactate are indicated. The bottom
row shows 13C and 1H spectra of L-[1-13C]lactate.
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the levels of polarization were typically greater than 20%. Lactate
samples were dissolved in 4 mL PBS at 180 °C and 10 bar to give a
concentration of 60 mM and pyruvate samples were dissolved in 6 mL
of HEPES buffer (40 mM HEPES, 94 mM NaOH, 30 mM NaCl and
100 mg/L EDTA) at 180 °C and 10 bar to give a concentration of
75 mM. The samples were cooled before 0.2 mL was injected within
10 s either into a 10 mm NMR tube or into a C57BL/6 mouse via a
tail-vein catheter.
Tumor Experiments. Female C57BL/6 mice (n =4 ,6 −8 weeks of
age; Charles River Ltd., Margate, UK) were injected subcutaneously in
the lower flank with 5 × 106 EL-4 cells (EL-4 is a murine lymphoma
cell line). At this location there was no detectable respiratory motion
in MR images. MRS was performed when the tumors had grown to a
size of ∼2c m 3 (which was reached typically at 10 days following
implantation).
3 One of the animals was treated with an intraperitoneal
injection of 67 mg etoposide (PCH Pharmachemie BV) per kg body
weight 24 h after the first MRS experiment, and the MRS measure-
ment was repeated 24 h after treatment. For MRS experiments,
animals were anesthetized with intraperitoneal injections of Hypnorm
(VetaPharma, Leeds, UK)/Hypnovel (Roche, Welwyn Garden City,
UK)/dextrose−saline (4%:0.18%) in a 5:4:31 ratio (10 mL/kg body
weight), and a catheter was inserted into the tail vein for injection of
hyperpolarized lactate or pyruvate. The body temperature of the
animals was maintained by blowing warm air through the magnet bore.
All experiments were conducted in compliance with a project license
and personal licenses issued under the Animals (Scientific Procedures)
Act of 1986 and were designed with reference to the United Kingdom
Co-ordinating Committee on Cancer Research guidelines for the
welfare of animals in experimental neoplasia. The work was approved
by a local ethical review committee.
MR Spectroscopy in Vivo. Experiments were performed using a
9.4 T vertical bore magnet (Oxford Instruments) interfaced to a
Varian UnityInova console (Palo Alto). A 13C-surface coil (diameter
24 mm) was placed directly over the tumor, and the animal holder was
then placed inside a 1H volume coil (Millipede, Varian Inc., length
6 cm, diameter 4 cm). Transverse 1H scout images were acquired
using a gradient-echo pulse sequence (30° pulse; repetition time (TR),
300 ms; echo time (TE), 2.2 ms; field-of-view (FOV) 35 mm ×
35 mm in a data matrix of 256 × 256 with two averages per increment;
slice thickness 2 mm and 21 transverse slices). 13C Data collection was
started 8 s after the beginning of a 200 μL i.v. injection of either
60 mM hyperpolarized [1-13C1,U-2H]lactate or [1-13C1]lactate or
75 mM hyperpolarized [1-13C]pyruvate and was continued for 75 s.
Spectra were acquired, in the case of pyruvate, using a nominal flip
angle of 10° at intervals of 1 s and in the case of lactate using a hetero-
nuclear 13C/1H spin−echo experiment which consisted of pairs of
spin−echo spectra, echo time 310 ms, collected with and without an
Figure 2. 13C/1H Heteronuclear spin−echo experiment with L-[1-13C]lactate and L-[1-13C,U-2H]lactate at thermal equilibrium. Signal intensity is
plotted versus echo time (TE). Frequency-selective 180° 1H pulses were applied at 4.11 ppm and at 1.33 ppm.
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angle pulse of each member of the pair and a 5.5 s delay between the
pairs. The spin−echo pulse sequence consisted of a nonselective 13C
excitation pulse, with a 10° nominal flip angle, a 4 ms adiabatic 13C
BIR4 180° refocusing pulse,
20 followed immediately by a 10 ms
hyperbolic secant (R = 10) 1H inversion pulse centered at 4.11 ppm
with the power adjusted either to 0 (H−) or optimized to provide
adiabatic inversion (H+) (Figure 2). The phase of the excitation pulse
was changed by 180° for the second member of each echo pair to
account for inversion of the remaining longitudinal magnetization
following the previous 13C refocusing pulse. Crusher gradients (5 G/cm,
2.5 ms) were placed around the refocusing pulses to destroy unwanted
coherences. Data were acquired from the spin−echoes (spectral width
8000 Hz, 512 complex points centered on the echo maximum) and also
from the free-induction decay (FID) obtained 1 ms after the excitation
pulse (acquisition time 1 ms, spectral width 8000 Hz, 512 complex
points) to assess the loss of longitudinal magnetization within the echo
pair. The order of the proton pulses within the echo pairs (H+/H− or
H−/H+) was also changed in some experiments. At the end of the
isotope exchange measurements, at ∼80 s after lactate injection,
apparent T2 relaxation times were measured using a multiecho sequence,
with an echo-spacing of 14 ms. Only even echoes were used for T2
analysis. In a separate group of animals, apparent R1 relaxation rates
were measured using a pulse-acquire sequence with a 10° nominal flip
angle, 13C pulse, and 10 s repetition time (acquisition time 1 ms,
spectral width 8000 Hz, 768 complex points).
Kinetic Analysis. Lactate peak integrals were calculated from
phase- and baseline-corrected spectra. The intensities of the deuterated
(SDL) and protonated (SHL) lactate signals were calculated from the
spin−echo signal intensities within each pair of echoes as:
=
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where SH− and SH+ are echo intensities measured in the absence and
presence of the 1H pulses, respectively. These equations were modified
to account for the effect of imperfect inversion of the 1H-coupled 13C
resonance following application of a 180° 1H pulse:
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where F is the fraction of inversion, with 1.0 being complete inversion.
In experiments with C2-protonated lactate (L-[1-13C]lactate) the value
of F was determined to be 0.88.
The data were fitted initially to a simple two-site exchange model
3
to obtain the rate constants describing label flux from C2-deuterated to
C2-protonated lactate (kDH) and from C2-protonated to C2-
deuterated lactate (kHD) and the longitudinal relaxation rates for the
deuterated (ρD) and protonated lactate (ρH) species. The relaxation
rates were assumed to be identical for both species (see Table 2).
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The apparent R1 relaxation rates were also calculated, using eq 6, from
pulse-acquire data (see above) and from the FID obtained
immediately following the excitation pulse in the spin−echo
experiments.
= −ρ S S e t
t
0
() (6)
Both the echo and FID intensities were corrected for the effect of the
low flip angle pulses on loss of polarization using eq 7.
=α S S /(cos )n
obs (7)
where S is the corrected polarization, Sobs is the observed polarization,
n is the number of the RF excitation pulses preceding the current
observation, and α is the pulse flip angle.
The simple two-site exchange analysis was, however, inadequate
since there was an increase in the echo intensity, relative to the FID
intensity, during the exchange time course, which implied a change in
the distribution of the observed lactate species. Therefore, a second
kinetic analysis was performed using the echo/FID (EF) ratios and in
which the two-site exchange model was modified to include an inflow
term. By using the EF ratio the effects of the RF pulses and T1
relaxation on the polarization were minimized and consequently
ignored in this analysis. For perdeuterated lactate (L-[1-13C,U-2H]-
lactate) this model can be written as:
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where klEFl represents the inflow term and EFDL and EFHL represent
respectively the detected C2-deuterated and C2-protonated lactate
within the tumor. The differential equations for this system can be
written in matrix form as:
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The measured values of EFDL and EFHL were fitted to the model
to obtain the exchange rate constants kDH, kHD and the inflow term
kIEFI.
■ RESULTS AND DISCUSSION
The 13C−1H J coupling constants between the C1 carbon and
the C2 proton and between the C1 carbon and the C3 protons
in lactate have been reported as 3.3 and 4.1 Hz, respectively.
21
These were confirmed from spectra of L-[1-13C1]lactate
(Figure 1) and L-[1-13C1,2-2H]lactate (data not shown). In a
heteronuclear 13C/1H spin−echo experiment with L-[1-13C1]-
lactate at thermal equilibrium, inversion of the 13C signal is
observed at an echo time (TE) of ∼310 ms (1/J1‑
13
C,2‑
1
H) when
a selective 180° proton pulse is applied at the resonant
frequency of the C2 proton (4.11 ppm), whereas no inversion
is observed with L-[1-13C1,U-2H]lactate (Figure 2). Thus, by
taking advantage of the relatively slow 13C spin−spin relaxation
rate (R2), the presence of a deuterium label at the C2 position
of lactate, which cannot be observed directly in the relatively
poorly resolved 13C spectra obtained in vivo (Figure 3), can
readily be detected from phase inversion of the spin-coupled
C1 13C resonance in the spin−echo experiment. The effect of J
coupling between the C1 carbon and the C3 protons is
observed at TE ≈ 250 ms (1/J1‑
13
C,3‑
1
H3), where application of a
selective 180° proton pulse at the resonant frequency of the C3
methyl protons (1.33 ppm) results in phase inversion of the C1
13C resonance (Figure 1B). The effect of this coupling between
the C1 carbon and the C3 protons was removed in experiments
performed in vivo by using perdeuterated lactate
([1-13C,U-2H]lactate), which also removed the requirement
for frequency-selective proton pulses.
Injection of hyperpolarized [1-13C]lactate into an EL4-
tumor-bearing mouse resulted in a low level of detectable
[1-13C]pyruvate (Figure 3a), which peaked at ∼2% of the total
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pyruvate peak intensities to a two-site exchange model
3 gave a
rate constant for flux of label from lactate to pyruvate of 0.0009
± 0.0005 s−1. Contrast this with experiments with hyper-
polarized [1-13C]pyruvate where, for much of the exchange
time course, the lactate peak intensity exceeded that of pyruvate
(Figure 3c,d). Fitting of these data gave a rate constant for the
exchange of 0.056 s−1, which is comparable to values measured
previously in this tumor model.
3,22
Figure 4a shows the Fourier transformed FID (Figure 4a (i))
and echo signals (Figure 4a (ii)) obtained from an EL4 tumor
following injection of L-[1-13C]lactate into a tumor-bearing
mouse, where the FID was measured immediately following the
low flip angle pulse in a heteronuclear 13C/1H spin−echo
experiment, and the echo was measured at 310 ms. Alternate
echoes were acquired with a 180° 1H pulse, which resulted in
nearly complete phase inversion of the spin-coupled hyper-
polarized C1 13C resonance (Figure 4a (ii) and c). The average
ratio of the echo signals obtained with and without the 180° 1H
pulse (H+/H−) for each echo pair (see Methods section) was
86 ± 7% when the loss of polarization between the pair of
echoes was ignored and 92 ± 7% when the echo signals were
first corrected for this loss of polarization using the FID
intensities obtained after each low flip angle pulse in the echo
pair. Conversion of the echo intensities obtained with and
without the 180° 1H pulse (H+/H−), using eqs 1 and 2, into the
concentrations of the C2-deuterated and C2-protonated
lactate species gave, due to imperfect phase inversion, an
artificial baseline for [1-13C,2-2H]lactate of ∼10%, when of
course there was no deuterated lactate present (Figure 4e).
This low but artifactual baseline remained constant through-
out the experiment (Figure 4g). In contrast, when
L-[1-13C,U-2H]lactate was injected, there was initially little
change in the hyperpolarized C1
13C resonance following
application of a 180° 1H pulse; however, as exchange of the
C2 deuterium with C2 protons in the endogenous lactate pool
proceeded, the 180° 1H pulse resulted in a progressively larger
decrease in the 13C resonance intensity (Figure 4d).
Conversion of these signal intensities into the concentrations
of the C2-deuterated ([1-13C1,U-2H]) and C2-protonated
([1-13C1,2-1H,3-2H3]) lactate species, using eqs 1 and 2,
showed an increasing signal from the C2-protonated species
during the exchange time course (Figure 4f,h). The exchange
rate constants calculated using eq 5 are summarized in Table
1. Correction for the artifactual baseline, due to imperfect
phase inversion, had only a modest effect on the fitted values
(eqs 3 and 4). The relative decrease in label flux after
etoposide treatment was similar to that observed previously
with [1-13C]pyruvate in this tumor model.
3,22 The calculated
relaxation rate (R1) from these three experiments was 0.037 ±
0.005 s−1 (n =3 )( T a b l e2 ) .
The ratio of the FID intensity to the intensity of the
echo decreased substantially such that by 45 s after lactate
injection the amplitudes of the echo and FID were comparable
Figure 3. Pulse and acquire 13C spectra from an EL-4 tumor following i.v. injection of 60 mM hyperpolarized L-[1-13C,U-2H]lactate (a) or
75 mM [1-13C]pyruvate (c). The lactate signal is at 185.08 ppm and the pyruvate signal at 172.9 ppm. There are also smaller signals from alanine at
178.48 ppm and pyruvate hydrate at 181 ppm. The corresponding time courses for label exchange between labeled lactate and pyruvate and between
labeled pyruvate and lactate are shown in (b) and (d), respectively.
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detecting a single lactate pool with relatively long T2. T2
measurements at ∼80 s postinjection gave an apparent T2
relaxation time of 0.605 ± 0.013 s (n = 2). In a previous study
in this tumor model, where we injected hyperpolarized
[1-13C]pyruvate, we observed two T2 components for pyruvate;
Figure 4. Detection of C2-protonated and C2-deuterated lactate species in a tumor in vivo using a heteronuclear spin−echo 13C/1He x p e r i m e n t
(TE = 310 ms). Spectra (a (i) and (ii)) and data analysis (c, e, and g) following i.v. injection of hyperpolarized C2-protonated lactate
(L-[1-13C]lactate). The spectra shown are the Fourier transformed FID, acquired 1 ms after the low flip angle pulse (a (i)), and the echoes
(a (ii)), which were acquired with and without 1H inversion pulses. In this series the 180° 1H pulses were applied in the order H−/H+
(see Methods section). Corresponding spectra (b (i) and (ii)) and data analysis (d, f, and h) following i.v. injection of hyperpolarized C2-
deuterated lactate (L-[1-13C,U-2H]lactate). In this series the 180° 1H pulses were applied in the order H+/H− (see Methods section). Panels
(c) and (d) show the FID and echo intensities with time (s) after lactate injection. Panels (e) and (f) show the calculated signal intensities due
to the C2-protonated and C2-deuterated lactate species, and panels (g) and (h) show the percentages of these species as a fraction of the total
lactate signal. The solid and dotted lines represent the best fit to the two-site exchange model (eq 5). The fitted exchange and relaxation rate
constants are shown in Tables 1 and 2, respectively.
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and a longer component (0.54 ± 0.16 s, 62 ± 22% of total
signal), where these measurements were made much earlier
after injection (15 − 30 s). An interpretation of these results is
that the short T2 component represents the blood pool, which
has an apparently short T2 because of flow effects, and therefore
that the relative increase in lactate echo amplitude observed
here was due to inflow of lactate from the blood pool into the
tumor extravascular space. Note that the T1’s determined from
the echo intensities are longer than those determined from the
FID intensities (Table 2), which is also consistent with this
notion. Note also that these changes in T2 had only a small
effect on the degree of peak inversion since changing the
sequence of the 180° 1H pulses (H+/H− or H−/H+) had no
effect on the measured exchange kinetics, as would be expected
from the relatively short echo spacing.
Reanalysis of the data shown in Figure 4 using the ratio of
the FID intensity to the intensity of the echo (echo/FID ratio;
EF) confirmed that this ratio increased over the exchange time
course (Figure 5a,b). The concentrations of the different lactate
species can be calculated from the EF ratios using eqs 1 and 2
and substituting for SDL, SHL, SH−,a n dSH+ with the
corresponding EF ratios. When this analysis was used for the
case where C2-protonated lactate was injected (L-[1-13C]-
lactate; Figure 5c), a progressive increase in the signal intensity
from this lactate species was observed, which can be explained
by inflow of the injected lactate into the tumor. These data and
the EF values obtained following injection of deuterated lactate
(L-[1-13C,U-2H]lactate; Figure 5d) were fitted to eq 9 to obtain
the exchange rate constants and a term representing lactate
inflow (Table 1). As noted for Figure 4e,g, the apparent
production of C2-deuterated lactate following injection of C2-
protonated lactate is due to imperfect phase inversion.
Deconvolution of the effects of flow, membrane transport,
and LDH kinetics on the observed exchange will require
measurements where the levels of the transporter or LDH have
been modulated, for example by changing LDH expression
using a PI3K inhibitor.
7
The relaxation rates (R1, R2) for the polarization in the
various lactate species, which were determined using pulse and
acquire spectra and also from the FID and echo intensities in
the heteronuclear spin−echo experiment, are shown in Table 2.
The R1 relaxation rates calculated from the spin−echo
experiments were faster than those calculated from the pulse
and acquire spectra. This presumably reflects imperfections in
the 13C refocusing pulses, which were delivered using a surface
coil, leading to an accelerated loss of z magnetization. However,
FID intensities within each echo pair were similar (Figure 4c,d),
showing that there was only minor loss of z magnetization
between each echo pair.
The sensitivity of this experiment, in which tumor LDH
activity was assessed by measuring exchange of the C2
deuterium with protons in endogenous lactate, was lower
than that in which exchange was measured directly between
[1-13C]pyruvate and endogenous lactate (Figure 3c,d) but
exceeded that when exchange was measured between [1-13C]-
lactate and endogenous pyruvate (Figure 3a,b). Consider the
signal intensities at 10 s following injection, when the
concentration of labeled lactate was at a maximum following
injection of hyperpolarized [1-13C]pyruvate (Figure 3d)).
At this time point the lactate signal was ∼50% of the injected
pyruvate signal intensity (Figure 3d). At the same time point in
the experiment with [1-13C1,U-2H]lactate the echo intensity
was ∼40% of the signal obtained immediately after the low
flip angle pulse, due to T2 relaxation. Of this signal ∼20% was
due to the C2-protonated lactate (L-[1-13C1,3-2H3]lactate
(Figure 4f), or ∼10% of the lactate signal that was observed
immediately after the low flip angle pulse. Contrast this with
the experiment where exchange was measured between
L-[1-13C]lactate and endogenous pyruvate, where the pyruvate
signal was only ∼2% of the signal from injected lactate
(Figure 3b).
Table 2. Apparent Spin−Lattice (R1) and Spin−Spin (R2) Relaxation Rates for the Different Labeled Lactate Species in Vitro
and in a Tumor in Vivo
L-[1-13C,U-2H]lactate (s−1) L-[1-13C,3-2H3]lactate (s−1) L-[1-13C]lactate (s−1)
R1
in vitro
a 0.021 ± 0.002 0.020 ± 0.001 0.023 ± 0.001
in vivo, pulse-acquire 0.023 0.025 0.035
in vivo, spin−echo (FID) 0.047 ± 0.002(n = 3) 0.042 0.054
in vivo, spin−echo (echo) 0.037 ± 0.005(n =3 ) − 0.038
R2
in vitro
b 0.75 ± 0.06(n =4 ) − 0.67 ± 0.06 (n =4 )
aMeasured with non-hyperpolarized samples of 30 mM lactate at 37 °C in phosphate-buffered saline, pH 7.1, 1 mM EDTA using an inversion−
recovery pulse sequence. These values are from single measurements, and the quoted errors are on the fit.
bMeasured with non-hyperpolarized
samples of 10 mM lactate at 25 °Ci n2H2O.
Table 1. Calculated Exchange Rates in Vivo Using Echo
Intensities and the Two-Site Exchange Model and Using the
Echo/FID (EF) Ratios and the Two-Site Exchange Model,
Modified to Include an Inflow Term, Following Injection of
L-[1-13C,U-2H]Lactate
two-site exchange model (fit to echo intensities) kDH (s−1) kHD (s−1)
tumor 1
a 0.020 0.018
tumor 2
a 0.024 0.018
tumor 2, treated
a 0.012 0
two-site exchange model, with an
additional inflow term (fit to EF
ratios) kl (s‑1)
kDH
(s‑1)
kHD
(s‑1)E F I
tumor 1 0.062 0.032 0.019 0.635
tumor 2 0.069 0.052 0.062 0.558
tumor 2, treated 0.107 0.022 0.007 0.544
aThe fitted R1 values from these experiments are shown, as an average,
in Table 2.
Journal of the American Chemical Society Article
dx.doi.org/10.1021/ja300222e | J. Am. Chem. Soc. 2012, 134, 4969−4977 4975■ CONCLUSIONS
We have described a new hyperpolarized substrate,
L-[1-13C,U-2H]lactate, in which measurements of exchange of
the C2 deuterium with the C2 protons in endogenous lactate,
in a hyperpolarized 13C/1H heteronuclear spin−echo experi-
ment, can be used to probe LDH kinetics in vivo. This
experiment has the advantage that it uses lactate, which can be
injected at physiological concentrations, and is more sensitive
than in the experiment in which exchange of the 13C label
between lactate and pyruvate is measured, where the size of the
endogenous pyruvate pool is a limiting factor. In addition, since
only a single peak is observed, imaging will be more
straightforward since chemical shift selection is not required.
Furthermore, at the lower magnetic field strengths used in the
clinic, the T2 relaxation times should be longer, and therefore
detection of the C2-protonated and C2-deuterated lactate
species should be more sensitive.
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